RECQL5 is a member of the RecQ family of DNA helicases and has key roles in homologous recombination, base excision repair, replication and transcription. The clinicopathological significance of RECQL5 expression in breast cancer is unknown. In the current study we have evaluated RECQL5 mRNA expression in 1977 breast cancers, and RECQL5 protein level in 1902 breast cancers [Nottingham Tenovus series (n=1650) and ER-cohort (n=252)].
INTRODUCTION
RecQ helicases are a highly conserved family of proteins with critical roles in the maintenance of genomic stability (1) (2) (3) (4) . RECQL5 is a key member of the mammalian RecQ helicase family (1) . It is a 3'-5' helicase with weak Holiday junction unwinding activity (1) . RECQL5 preferentially unwinds the lagging strand of DNA at replication fork structures and can promote strand exchange in vitro (5) . Three isoforms of RECQL5 have been identified; RECQL5α (410aa), RECQL5β (435aa) and RECQL5γ (991aa) (6) . Whereas RECQL5α and RECQL5γ are cytoplasmic, RECQL5β isoform has nuclear localisation (6) . RECQL5β (here in referred to as RECQL5) interacts with multiple DNA repair and metabolising proteins including RAD51, RAD50, PARP1, FEN1, RNA Polymerase II, WRN, BLM and Mre11, NBS1, PCNA, TopIIa and Top IIIa/b (1) . RECQL5 has important roles in homologous recombination (HR), base excision repair (BER), DNA replication and transcription (1) . Evidence for a role in HR includes findings that RECQL5 deficient cells have an increased rate of sister chromatid exchange (7) , and that depleted cells accumulate H2Ax and RAD51 foci (8) . Mechanistically RECQL5's function in HR can be proposed from in vitro studies showing that RECQL5 physically interacts with RAD51, causing an ATPase dependent disruption of RAD51 mediated presynaptic filament formation and hence has anti-recombinase activity (9) similar to Bloom syndrome helicase (BLM) (7) . Further RECQL5 associates with the MRN complex and inhibits MRE11 exonuclease activity (10) , which may also contribute to the HR function of RECQL5. Interestingly while the MRN complex is required to bring RECQL5 to sites of DSBs it's recruitment is independent of the helicase activity (11) . RECQL5 may also have a role in base excision repair (BER). It's precise function in this pathway is not clear but RECQL5 interacts with the long patch BER proteins PCNA and FEN1, it's interaction stimulating FEN1 activity, and RECQL5 co-localises with FEN1 after oxidative damage of DNA (12) . In addition the short patch BER protein XRCC1 is retained at sites of oxidative damage in the absence of RECQL5 and expression of PARP1 and XRCC1 maybe regulated by RECQL5 (13) . A role in protecting cells from DNA replication stress has also been shown for RECQL5. RECQL5 foci increase following replication stress and overexpressing RECQL5 can overcome thymidine induced replication stress (14) . Likewise RECQL5 can prevent spontaneous replication fork collapse and RECQL5 depleted cells are hypersensitive the DNA replication inhibitor camptothecin, (15, 16) . RECQL5 has also been implicated in regulation of transcription elongation and can supress genomic instability associated with transcriptional stress (2, 17, 18) .
Germline mutation of three of the RecQ helicases (BLM, WRN and RECQL4) leads to cancer predisposition syndromes namely Bloom syndrome, Werner syndrome and RothmundThomson syndrome (3, 4) . Although RECQL5 helicase has not been associated with any disease phenotype, in preclinical studies, RECQL5 deficient mice cells show increased levels of spontaneous double strand breaks, are susceptible to gross chromosomal rearrangements and are prone to develop lymphomas and various solid tumours including breast cancer (8) (19) .
We hypothesised that RECQL5 may influence breast cancer pathogenesis. In the current study we have evaluated RECQL5 mRNA expression in 1950 breast cancers, and RECQL5 protein level in 1902 breast cancers. We provide the first clinical evidence that RECQL5 may influence the development of aggressive breast cancer and have prognostic significance particularly in ER+ breast cancers. In addition we show that exogenous expression of RECQL5 in MCF10A cells can drive proliferation supporting a oncogenic function for RECQL5 in breast cancer.
MATERIALS AND METHODS
RECQL5 and mRNA expression: RECQL5 mRNA expression was investigated in METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort. The METABRIC study protocol, detailing the molecular profiling methodology in a cohort of 1980 breast cancer samples is described by Curtis et al (20) . Patient demographics are summarized in supplementary Table S1 of supporting information. ER positive and/or lymph node negative patients did not receive adjuvant chemotherapy. ER negative and/or lymphnode positive patients received adjuvant chemotherapy. For this cohort, the mRNA expression was hybridized to Illumina HT-12 v3 platform (Bead Arrays), and the data were pre-processed and normalized as described previously (20) . RECQL5 expression was evaluated in this data set (RECQL5 probe ID: ILMN_1697682). The probe was a perfect match and quality for its target, having a GC content of 58% , 0 SNPs and it does not possess a polyG tail at the end. Samples were classified into the intrinsic subtypes based on the PAM50 gene list. A description of the normalization, segmentation, and statistical analyses was previously described (20) . Real time RT-qPCR was performed on the ABI Prism 7900HT sequence detection system (Applied Biosystems) using SYBR1 Green reporter. All the samples were analysed as triplicates. The Chi-square test was used for testing association between categorical variables, and a multivariate Cox model was fitted to the data using as endpoint breast cancer specific death. Xtile (Version 3.6.1) was used to identify a cut-off in gene expression values such that the resulting subgroups have significantly different survival courses. In addition, a corrected P-value was produced for each analysis by using Monte-Carlo Cross Validation (MCCV) simulations ( 50 random populations) in X-tile to avoid the problem of over fitting and finding aberrantly low p-value due to the analysis of multiple cut-points (Camp et al,2004 ) . The two-fold cross validation was used to randomly split the data in to two halves and find the optimal cut-point of one half, and then divide the other half according to this cut-point. Then, the optimal cutpoint of the second half was found and the first halve was similarly divided. Finally, a survival analysis of the entire dataset was performed based on the average of the optimal cut-points obtained from the MCCV simulations (Camp et al ,2004 ).
RECQL5 protein expression in breast cancer:
The study was performed in a consecutive series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series.
Patient demographics are summarised in Supplementary Table S2 . This is a wellcharacterized series of patients with long-term follow-up that have been investigated in a wide range of biomarker studies (21) (22) (23) (24) . All patients were treated in a uniform way in a single institution with standard surgery (mastectomy or wide local excision), followed by The negative control ensured that all the staining was produced from the specific interaction between antibody and antigen.
Evaluation of immune staining:
The tumour cores were evaluated by two scorers (AA and TAF) and the concordance between the two scorer was excellent (k = 0.79). Whole field inspection of the core was scored and intensities of nuclear staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage of each category was estimated (0-100%). H-score (range 0-300) was calculated by multiplying intensity of staining and percentage staining. RECQL5, RAD51 and TOPO2A expression was categorised based on the frequency histogram distributions. A median H score of ≥10 was taken as the cut-off for high RECQL5 and a median H score of ≥8 was taken as the cut-off for high RAD51 nuclear expression. For TOPO2A >25% staining cells were taken as high TOPO2A expression. Not all cores within the TMA were suitable for IHC analysis as some cores were missing or lacked tumour (<15% tumour).
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL).
Where appropriate, Pearson's Chi-square, Fisher's exact, Student's t and ANOVA one way tests were used. Cumulative survival probabilities were estimated using the Kaplan-Meier method, and differences between survival rates were tested for significance using the log-rank test. Multivariate analysis for survival was performed using the Cox proportional hazard model.
The proportional hazards assumption was tested using standard log-log plots. Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable. All tests were two-sided with a 95% CI and a p value <0.05 considered significant. For multiple comparisons, p values were adjusted according to Holm-Bonferroni correction method (26) . Minus reverse transcriptase (-RT) control was used to rule out genomic DNA contamination. We then proceeded to survival analysis in METABRIC cohort. High RECQL5 mRNA expression was associated with poor breast cancer specific survival (BCSS) (p<0.0001) in the whole cohort [ Figure 1B ]. In the ER+ sub-group, high RECQL5 mRNA expression was found to be associated with poor BCSS (p<0.0001) [ Figure 1C ]. In the ER+ sub-group that received adjuvant endocrine therapy, high RECQL5 mRNA expression remained associated with poor BCSS (p<0.001) [ Figure 1D ]. However, in ER-sub-group, RECQL5 mRNA expression did not significantly influence outcome in the ER-cohort, including ER-patients who received chemotherapy (p=0.116 and p=0.213 respectively) [ Figure 1E , 1F].
RESULTS

High
In the multivariate Cox regression analysis, that included other validated prognostic factors, RECQL5 mRNA expression was a powerful independent predictor for breast cancer specific survival in the whole cohort (p=0.038), ER+ sub-group (p=0.046) but not in the ER-sub-group (p=0.615) ( Table 2) .
Together the data provides evidence that RECQL5 mRNA level has clinicopathological significance and influence prognosis, particularly in ER+ breast cancers. We proceeded to evaluate RECQL5 protein expression in breast cancers. Figure 2C) . Taken together, the data suggest that RECQL5 is a marker of proliferation and could have prognostic and/or predictive significance in human breast cancers. We proceeded to IHC investigation in human tumours. To provide evidence for the specificity of the anti-RECQL5 antibody used for IHC studies, we generated RECQL5 knockdown (KD) MCF7 cells using two siRNA constructs. As shown in Figure 2D , control cells have robust RECQL5 expression seen as a single band while RECQL5 KD cells show almost complete loss of this band -demonstrating the specificity of the RECQL5 antibody.
We observed nuclear only localization of RECQL5 protein in breast cancers [ Figure 2D ].
There was no cytoplasmic staining in breast tumours. We initially investigated RECQL5 RECQL5 co-expression with RAD51 or TOPO2A in sporadic breast cancer: RECQL5 physically interacts with RAD51 and disrupts RAD51 mediated presynaptic filament formation (1, 9) . Tumours with high RECQL5-low RAD51 nuclear protein levels were significantly associated with high grade, high mitosis and pleomorphism (ps<0.05) [ Table 3 ]. Tumours with low RECQL5-low RAD51 nuclear protein levels were significantly associated with tubule formation, NPI>3.4 and ER/PR negativity (ps<0.5) [ Table 3 ]. In univariate analysis, tumours with high RECQL5-low RAD51 nuclear protein levels were associated with poor breast cancer specific survival in the whole cohort (p=0.003) [ Figure 2E ]. In sub-group analysis, ER+ tumours with high RECQL5-low RAD51 nuclear protein levels were associated with poor breast cancer specific survival (p=0.010) [ Figure 2F ]. In ER-cohort, RECQL5-RAD51 coexpression did not influence survival (p=0.628) [Supplementary Figure S1D] . We have previously shown a direct interaction between RECQL5 and Topoisomerase IIα (TOP2A) where RECQL5 specifically stimulated the decatenation activity of TOP2A (28) . Tumours with low RECQL5-high TOPO2A were significantly associated with high grade, high mitotic index, Table S6 ).
de-differentiation tumour type, high risk NPI and PR negativity (Supplementary
In univariate analysis, RECQL5-TOPO2A co-expression did not influence survival (Supplementary Figures S1E, S1F , S1G)
In multivariate analysis (Table 4) , RECQL5-RAD51 co-expression remained statistically significant independent marker of prognosis (p=0.022) in the whole cohort. NPI and HER-2 expression were other factors independently associated with breast cancer specific survival (ps 0.001 and 0.0001 respectively). In the ER+ sub-group, RECQL5-RAD51 co-expression was of borderline significance (p=0.07), but not in the ER-sub-group (p=0.172).
DISCUSSION
RECQL5 is a key member of the RecQ family of DNA helicases (1) (2) (3) (4) . RECQL5 is a multifunctional protein with roles in DNA replication, chromosomal segregation, DNA repair (including homologous recombination, single strand break repair and base excision repair) and transcription. Emerging pre-clinical evidence suggests that RECQL5 is a tumour suppressor.
RECQL5 deficient mice are predisposed to lymphomas and solid tumours including breast tumours (1-4). In humans, polymorphisms within the RECQL5 gene may predispose an individual to cancer including: osteosarcomas, laryngeal carcinomas and breast cancers (29) (30) (31) (32) . In a recent study in colorectal cancers, low RECQL5 expression was observed at the mRNA and protein levels (19) . The authors concluded that RECQL5 deficiency may predispose to colorectal cancer. However, the study had several limitations, including a small cohort and lack of clear evidence of clinicopathological associations or survival outcomes (19) .
The clinicopathological significance of RECQL5 in sporadic breast cancer is unknown. In the current study we have comprehensively evaluated RECQL5, and unravelled its complex role in breast cancers. At the mRNA level, we observed high expression in 34% of tumours. High RECQL5 mRNA expression was significantly associated with aggressive phenotypes and adverse survival. The prognostic significance was particularly pronounced in ER+ sub-group, supporting the observation that high RECQL5 mRNA expression was more likely in ER+/HER2 -/high proliferation Geneufu sub-type tumours. At the protein level, we observed high RECQL5 levels in 53.7% of breast cancers. In contrast to mRNA expression data, although low RECQL5 expression was associated with aggressive phenotype, RECQL5
protein alone did not influence survival outcomes in patients. The data suggest that RECQL5 may be subjected to complex post-transcriptional regulation. Another possibility is that the complex role of RECQL5 may operate in the context of RAD51. RECQL5 directly interacts with RAD51 (9) and the anti-recombinogenic role of RECQL5 may be active through disruption of RAD51 mediated presynaptic filament formation during HR (33) . Therefore, we conducted RECQL5-RAD51 co-expression studies and observed that tumours with high RECQL5/low RAD51 not only manifest aggressive phenotypes but were also associated with poor survival. In sub-group studies, similar to mRNA data, the prognostic significance was more pronounced in ER+ breast cancer but not in ER-tumours. Consistent with high RECQL5
being associated with aggressive phenotypes, over expression of RECQL5 in the normal breast cell line MCF10A increased proliferation. Interestingly RAD51 is reported as having relatively low expression in MCF10A cells (34) and the functional relationship between RECQL5, RAD51, proliferation, recombination and tumourigenesis will be the subject of future investigations. Taken together, the data provides the first clinical evidence that RECQL5 may influence breast cancer pathogenesis.
RECQL5 interacts with and is a general transcription elongation factor for RNA Pol II (2, 17, 18) . Loss of RECQL5 leads to a genome-wide increase in the average rate of gene transcription, transcriptional stress and recombination (17) suggesting RECQL5 has a function in resolving such stress. RNA polymerases generate positive supercoiling ahead of the transcription apparatus, which in turn feeds back to reduce the processional rate of RNA polymerase.
Topoisomerases are ubiquitous enzymes that remove supercoiling and therefore are required for normal transcription elongation. Specifically, type II topoisomerases generate transient protein-concealed double strand breaks while removing torsional stress from the DNA and collisions with the transcription apparatus can convert these protein-DNA complexes into permanent DNA strand breaks (35) . Previously, we showed a direct interaction between RECQL5 and Topoisomerase IIα (TOP2A) specifically stimulated the decatenation activity of TOP2A (28) . TOP2A expression is a marker for proliferation and has been analyzed in a number of breast cancer studies in part because it lies in close proximity to the HER2 gene on chromosome 17. Therefore, we were interested in evaluating if there were any expression correlations between RECQL5, which also resides on chromosome 17 (17q25.1), and TOP2A expression in our breast cancer cohorts. Interestingly, high grade tumours are more often scored as RECQL5-and TOP2A+, than any other expression pattern. This may reflect the fact that loss of RECQL5 promotes transcriptional stress. Additionally, while TOP2A is known as a marker for proliferation, loss of RECQL5 may make these cells more dependent on TOP2A to relieve transcriptional stress. Thus in this subgroup of patients, it would be interesting to evaluate the efficacy of topoisomerase targeted therapies, if in fact these tumours are more dependent on topoisomerase activities than other tumour types cells.
In conclusion, our data provides evidence that RECQL5 could be a promising biomarker in breast cancer and needs further investigation as a potential drug target. 
